Korean J Urol.  2006 Apr;47(4):353-357. 10.4111/kju.2006.47.4.353.

The Influence of Age and Prostate Volume on the Cancer Detection Rate in Korean Men with PSA Levels of 4.0 to 10.0ng/ml: a Multicenter, Retrospective Study

• Seong DH
• Cho JS
• Hong SJ
• Chung BH
• Choi YD
• Kim SJ
• Lee DH
• Cho IR
• Kim YS
• Kim CI
• Kim SI
• Song JM
• Cheon SH
• Kim HS

• KMID: 1997141
• DOI: http://doi.org/10.4111/kju.2006.47.4.353

Abstract

PURPOSE
We retrospectively investigated how patients age and prostate volume influence on the cancer detection rate in Korean men with prostate-specific antigen (PSA) levels of 4.0 to 10.0ng/ml.
MATERIALS AND METHODS
791 Korean men who underwent transrectal ultrasound guided prostate biopsies (TRBx) at 12 medical centers were analyzed retrospectively during the previous 10 years. TRBx were performed in cases with PSA levels of 4.0 to 10.0ng/ml. The biopsy-proven cancer patient group was compared to the non-cancer patient group according to age, PSA, prostate volume and PSAD.
RESULTS
Among the 791 patients who underwent TRBx, prostate cancer was detected in 123 patients (15.5%). The mean age (cancer group vs non-cancer group=69.1 vs 63.8 year-old), prostate volume (38.0 vs 42.5ml, respectively) and PSAD (0.21 vs 0.18ng/ml/ml, respectively) were found in statistically significant between the two groups. The cancer detection rate (20.1%) in the small prostate (less than 40ml) was significantly higher than that (10.3%) of the large prostate. The cancer detection rate was significantly increased with age: from 14.4% for the 50 to 59 year-old patients to 31.6% for the 80 or more year-old patients.
CONCLUSIONS
The cancer detection rate in Korean men with a gray zone PSA level is lower than that of Caucasians. However, regarding the detection of prostate cancer in Korean men, the older age group and the patients with less than 40ml of prostate volume among the patients with gray zone PSA levels are considered as the important factors to decide whether biopsy of prostate is needed.

Keyword

Prostate-specific antigen; Prostate cancer

MeSH Terms

Biopsy
Humans
Male
Middle Aged
Prostate*
Prostate-Specific Antigen
Prostatic Neoplasms
Retrospective Studies*
Ultrasonography
Prostate-Specific Antigen

Reference

1. Catalona WJ, Hudson MA, Scardino PT, Richie JP, Ahmann FR, Flanigan RC, et al. Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: receiver operating characteristic curves. J Urol. 1994. 152:2037–2042.

2. Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol. 1994. 151:1283–1290.

3. Meshref AW, Bazinet M, Trudel C, Aronson S, Peloquin F, Nachabe M, et al. Role of prostate-specific antigen density after applying age-specific prostate-specific antigen reference ranges. Urology. 1995. 45:972–979.

4. Schroder FH, Van der Cruijsen-Koeter I, De Koning HJ, Vis AN, Hoedemaeker RF, Kranse R. Prostate cancer detection at low prostate specific antigen. J Urol. 2000. 163:806–812.

5. Morote J, Raventos CX, Lorente JA, Lopez-Pacios MA, Encabo G, De Torres I, et al. Comparison of percent free prostate specific antigen and prostate specific antigen density as methods to enhance prostate specific antigen specificity in early prostate cancer detection in men with normal rectal examination and prostate specific antigen between 4.1 and 10ng/ml. J Urol. 1997. 158:502–504.

6. Egawa S, Matsumoto K, Yoshida K, Iwamura M, Kuwao S, Koshiba K. Results of transrectal ultrasound-guided biopsies and clinical significance of Japanese prostate cancer. Jpn J Clin Oncol. 1998. 28:666–672.

7. Kobayashi T, Nishizawa K, Ogura K, Mitsumori K, Ide Y. Detection of prostate cancer in men with prostate-specific antigen levels of 2.0 to 4.0ng/ml equivalent to that in men with 4.1 to 10.0ng/ml in a Japanese population. Urology. 2004. 63:727–731.

8. Yamamoto S, Ito T, Aizawa T, Noda K, Umezu K, Ohtsuru N, et al. Does transrectal ultrasound guided eight-core prostate biopsy improve cancer detection rates in patients with prostate-specific antigen levels of 4.1-10ng/ml? Int J Urol. 2004. 11:386–391.

9. Jung YJ, Jeong H, Chung J, Lee SB, Lee SE, Kim SH. The outcome of TRUS-guided sextant biopsy according to prostate volume. Korean J Urol. 2000. 41:505–511.

10. Jung BC, Kim TH, Jeong SJ, Kwak C, Lee SE. The clinical usefulness of the prostate-specific antigen density, digital rectal examination, and transrectal ultrasonography in the screening test of prostate cancer in Korea. Korean J Urol. 2002. 43:14–18.

11. Lee SC, Lee SC, Kim WJ. Value of PSA density, PSA velocity and percent free PSA for detection of prostate cancer in patients with serum PSA 4-10ng/ml patients. Korean J Urol. 2004. 45:747–752.

12. Eskicorapci SY, Guliyev F, Akdogan B, Dogan HS, Ergen A, Ozen H. Individualization of the biopsy protocol according to the prostate gland volume for prostate cancer detection. J Urol. 2005. 173:1536–1540.

13. Blijengerg BG, Lilja H, Neels H, Stenman UH. Quality assessment for prostate-specific antigen (PSA) in relation to ERSPC: report of the PSA committee. BJU Int. 2003. 92:Suppl 2. 66–70.

14. Oesterling JE. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol. 1991. 145:907–923.

15. Yu HJ, Lai MK. The usefulness of prostate-specific antigen (PSA) density in patients with intermediate serum PSA level in a country with low incidence of prostate cancer. Urology. 1998. 51:5A Suppl. 125–130.

16. Min YK, Kim JS, Rim JS. The effectiveness of prostate biopsy in patients with negative digital rectal examination and serum prostate specific antigen concentration between 4 and 10ng/ml. Korean J Urol. 1999. 40:853–857.

17. Standaert B, Alwan A, Nelen V, Denis L. Prostate volume and cancer in screening programs. The Prostate. 1997. 33:188–194.

18. Karakiewicz PI, Bazinet M, Aprikian AG, Trudel C, Aronson S, Nachabe M, et al. Outcome of sextant biopsy according to gland volume. Urology. 1997. 49:55–59.

19. Ung JO, San Francisco IF, Regan MM, DeWolf WC, Olumi AF. The relationship of prostate gland volume to extended needle biopsy on prostate cancer detection. J Urol. 2003. 169:130–135.

20. Uzzo RG, Wei JT, Waldbaum RS, Perlmutter AP, Byrne JC, Vaughan ED Jr. The influence of prostatic size on cancer detection. Urology. 1995. 46:831–836.

21. Mariappan P, Chong WL, Sundram M, Mohamed SR. Increasing prostate biopsy cores based on volume vs the sextant biopsy: a prospective randomized controlled clinical study on cancer detection rates and morbidity. BJU Int. 2004. 94:307–310.

22. Oesterling JE, Jacobsen SJ, Cooner WH. The use of age-specific reference ranges for serum prostate specific antigen in men 60 years old or older. J Urol. 1995. 153:1160–1163.

23. Mettlin C, Lee F, Drago J, Murphy GP. The American Cancer Society National Prostate Cancer Detection Project. Findings on the detection of early prostate cancer in 2425 men. Cancer. 1991. 67:2949–2958.